Introduction {#sec1}
============

Glucuronidation of carboxylic acid drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) is a major conjugation reaction catalyzed by multiple UDP-glucuronosyltransferases (UGTs).^[@ref1]−[@ref5]^ The resultant 1-β-*O*-acyl glucuronides (AGs) are of great importance not only in drug metabolism and excretion but also because of their toxicological consequences. AGs are chemically reactive, electrophilic metabolites that undergo degradation reactions (hydrolysis and intramolecular migration of the 1-β-*O*-acyl linkage)^[@ref6],[@ref7]^ as well as covalent binding to cellular macromolecules and thus may be implicated in adverse drug reactions (ADRs) such as drug-induced liver injury^[@ref8]−[@ref15]^ and intestinal injury.^[@ref16]−[@ref18]^ Some NSAIDs have been withdrawn from the market because of ADRs, including liver and renal toxicities and anaphylaxis.^[@ref8],[@ref19]−[@ref21]^ Since a pioneering study on the excellent correlation between the extents of covalent binding of AGs to albumin and their degradation rate constants,^[@ref22]^ there have been several thorough studies on the structure--rate constant relationships of AGs as well as prediction and evaluation studies of the toxicological risks posed by AGs.^[@ref23]−[@ref29]^ The mechanism of the covalent binding of AGs to and the binding sites on albumin have been reported,^[@ref30]−[@ref33]^ and the modification of albumin has been demonstrated to proceed via both the direct acylation^[@ref34]^ and the Schiff base-mediated glycation^[@ref35]^ mechanisms. Recently, AG-mediated cytotoxic mechanisms involving oxidative stress have been reported.^[@ref36],[@ref37]^ In addition, AGs play roles in drug--drug interactions via membrane transporters^[@ref17],[@ref38],[@ref39]^ as well as through CYP2C8 inhibition.^[@ref40]−[@ref42]^ Various factors that affect the safety of AGs, including the rates of formation, elimination, and aglucuronidation; their intrinsic reactivity; and the potential proteins being targeted,^[@ref43]^ as well as the molecular mechanisms underlying AG-induced toxicities,^[@ref44]^ all remain to be elucidated fully.

ALP, (*RS*)-2-{4-\[(2-methylallyl)amino\]phenyl}propanoic acid **1** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), is a racemic drug categorized as a 2-arylpropanoic acid-class NSAID and has the distinctive molecular characteristic of possessing a 4-monoalkenylamino group in a structure that closely resembles that of ibuprofen. The drug **1** has been used in several countries such as France, Luxembourg, and Japan; in Japan, **1** was approved in 2014 as a switch OTC commonly used to treat conditions such as rheumatism, arthralgia, and lumbago. The drug **1** is reported to exhibit a more potent analgesic effect than ibuprofen^[@ref45]^ and to exert a dual anti-inflammatory action by inhibiting both cyclo-oxygenase-2 and phospholipase A~2~,^[@ref46],[@ref47]^ thereby possibly causing interesting analgesic, antipyretic, and anti-inflammatory actions^[@ref46],[@ref48]−[@ref50]^ different from those of commonly used NSAIDs. Pharmacokinetic studies in patients after p.o. administration of **1** have revealed rapid absorption, a short time to maximum plasma level, a short biological half-life, and excretion of the corresponding ALP acyl glucuronide **5** as a major urinary metabolite.^[@ref51]^ The acyl glucuronide **5** is most likely the diastereomers (2*RS*)-**5** derived from **1**, but little is known about the structure and stereochemistry of **5**. Furthermore, the membrane transporter(s) for **1** and (2*RS*)-**5**, the UGT isozyme(s) involved in glucuronidation, and the possible stereoselectivities of these biological systems toward **1** (enantioselective) and (2*RS*)-**5** (diastereoselective) all remain to be elucidated. However, **1** has been reported to show high permeability comparable to that of ibuprofen in Caco-2 cell studies.^[@ref52],[@ref53]^ The synthesis and stereochemical determination of (2*RS*)-**5**, as well as the chiral resolution of **1**, are thus of great importance in pharmacokinetic and toxicological studies of **1**.

![Structure of ALP **1**.](ao-2018-00443d_0001){#fig1}

Herein, we report the synthesis of (2*RS*)-**5** from **1** using our chemo-enzymatic method,^[@ref54]^ the stereochemistry of both (2*RS*)-**5** and **1**, and the intrinsic degradation rate constants of (2*R*)-**5** and (2*S*)-**5** under physiological conditions (at pH 7.40 and 37 °C).

Results and Discussion {#sec2}
======================

Synthesis of ALP AGs (2*RS*)-**5** {#sec2.1}
----------------------------------

Two diastereomeric mixtures of (2*RS*)-**5** were synthesized using our two-step chemo-enzymatic method,^[@ref54],[@ref55]^ as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. In the first step, condensation of the cesium salt of **1** with methyl 2,3,4-tri-*O*-acetyl-1-bromo-1-deoxy-α-[d]{.smallcaps}-glucopyranuronate **2** afforded the corresponding methyl acetyl derivatives (2*RS*)-**3** as an approximately 1:1 mixture of the diastereomers in a modest 53% yield, without production of the corresponding α-anomers (based on ^1^H NMR data). The anomeric β-configurations of the diastereomers (2*RS*)-**3** were confirmed by ^1^H NMR. The *J* values of both anomeric protons were 8.2 Hz,^[@ref56]^ and the chemical shifts were δ 5.85 and 5.78 for (2*S*)-**3** and (2*R*)-**3**, respectively. We were unable to separate the diastereomers (2*RS*)-**3** using conventional methods, and thus we examined enzymatic removal of the sugar-protecting groups as the next step toward (2*RS*)-**3**. It is important to remove the protecting groups without affecting the 1-β-*O*-acyl linkage. As shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, (2*RS*)-**3** was not detected following treatment with lipase AS Amano (LAS) at the optimal temperature of 40 °C for 1.33 h of incubation, and the products and yields (%) were the partially *O*-deacetylated intermediates (48%), the fully *O*-deacetylated derivatives (2*RS*)-**4** (43%), and the liberated parent carboxylic acid **1** (9%). The chemo-selectivity of LAS toward the *O*-acetyl groups was not improved by using cosolvents (1,4-dioxane, *N*,*N*-dimethylformamide, and MeOH) other than dimethyl sulfoxide (DMSO) (data not shown). In contrast, the use of carboxylesterase from *Streptomyces rochei* (CSR) at the optimal temperature of 50 °C for 1.33 h resulted in 16% unreacted (2*RS*)-**3**; the products were fully *O*-deacetylated derivatives (2*RS*)-**4** (64%) and intermediates (20%). No liberation of the parent carboxylic acid **1** was detected, indicating that CSR exhibited much higher chemo-selectivity toward the *O*-acetyl groups than did LAS. Furthermore, CSR exhibited higher hydrolytic activity toward the partially *O*-deacetylated intermediates than toward (2*RS*)-**3**, whereas LAS exhibited the opposite preference for the substrates. Therefore, concurrent use of LAS and CSR (1:10, w/w) synergistically accelerated *O*-deacetylation to afford (2*RS*)-**4** in 94% yield in 7 h and a small amount of **1** (3%). To diminish the liberation of **1** catalyzed by LAS, the initial reaction temperature of 40 °C was maintained for 0.25 h and then was raised to 50 °C to deactivate the hydrolytic activity of LAS. As was reported previously,^[@ref54],[@ref55]^ DMSO was proved to be a good choice of cosolvent for the enzymatic deacetylation of the *O*-acetyl groups of (2*RS*)-**3**.

![Synthesis of ALP AGs (2*RS*)-**5**\
Reagents: (a) (i) 0.50 M Cs~2~CO~3~ (aq), EtOH, room temperature, 10 min, (ii) DMSO, room temperature, 1 h (53%); (b) LAS and CSR, 20 mM sodium citrate (pH 5.0), 15% (v/v) DMSO, 40 °C for 0.25 h and then 50 °C for 6.75 h (94%); and (c) Chirazyme L-2 CB, 20 mM sodium citrate (pH 5.0), 10% (v/v) DMSO, 40 °C for 1 h (99%).](ao-2018-00443d_0005){#sch1}

###### Enzyme-Catalyzed Hydrolytic Deprotection of the *O*-Acetyl Groups of (2*RS*)-**3**

![](ao-2018-00443d_0007){#GRAPHIC-d184e774-autogenerated}

  enzyme                                      concn (mM)[a](#t1fn1){ref-type="table-fn"}   temp (°C)                                time (h)[b](#t1fn2){ref-type="table-fn"}   product yields (%)[c](#t1fn3){ref-type="table-fn"}
  ------------------------------------------- -------------------------------------------- ---------------------------------------- ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------
  LAS[d](#t1fn4){ref-type="table-fn"}         1.1                                          40                                       1.33                                       (2*RS*)-**4** (43), (2*RS*)-**3** (nd[e](#t1fn5){ref-type="table-fn"}), **1** (9), others[f](#t1fn6){ref-type="table-fn"} (48)
  CSR[d](#t1fn4){ref-type="table-fn"}         1.1                                          50                                       1.33                                       (2*RS*)-**4** (64), (2*RS*)-**3** (16), **1** (nd), others[f](#t1fn6){ref-type="table-fn"} (20)
  LAS + CSR[g](#t1fn7){ref-type="table-fn"}   1.1                                          40--50[h](#t1fn8){ref-type="table-fn"}   7.0                                        (2*RS*)-**4** (94), (2*RS*)-**3** (nd[e](#t1fn5){ref-type="table-fn"}), **1** (3), others[f](#t1fn6){ref-type="table-fn"} (3)

Initial concentration of (2*RS*)-**3** in 20 mM sodium citrate buffer (pH 5.0) containing 15% (v/v) DMSO.

Incubation time.

Yields based on high-performance liquid chromatography (HPLC) analysis.

Enzyme: 10 mg/mL.

nd = not detected.

Others: partially *O*-deacetylated intermediates.

Enzymes: LAS (0.50 mg/mL) and CSR (5.5 mg/mL).

40 °C for 15 min and then increased to 50 °C.

As the final step, enzymatic chemo-selective hydrolysis of the methyl ester of (2*RS*)-**4** was examined using pig liver esterase (PLE), lipase type-B from *Candida antarctica* (CALB), and Chirazymes L-5 CA and L-2 CB, using DMSO as a cosolvent. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, Chirazyme L-5 CA showed the lowest hydrolytic activity toward (2*RS*)-**4**. PLE showed a high hydrolytic activity comparable with those of CALB and Chirazyme L-2 CB but lower chemo-selectivity; the parent carboxylic acid **1** (3%) was concomitantly liberated. DMSO was the best cosolvent for these enzymatic reactions: in the PLE-catalyzed reaction, the amount of **1** increased to 14% when MeOH was used as the cosolvent while keeping all other conditions unchanged and the hydrolytic activity of PLE was almost inhibited when *tert*-BuOH was used as the cosolvent (data not shown).

###### Enzyme-Catalyzed Hydrolytic Deprotection of the Methyl Ester of (2*RS*)-**4**

![](ao-2018-00443d_0008){#GRAPHIC-d184e993-autogenerated}

  enzyme[a](#t2fn1){ref-type="table-fn"}   time (h)[b](#t2fn2){ref-type="table-fn"}   product yields (%)[c](#t2fn3){ref-type="table-fn"}
  ---------------------------------------- ------------------------------------------ --------------------------------------------------------------------------------------------------------------------
  PLE                                      1.0                                        (2*RS*)-**5** (97), **1** (3), (2*RS*)-**4** (nd[d](#t2fn4){ref-type="table-fn"})
  CALB                                     0.50                                       (2*RS*)-**5** (99), **1** (nd[d](#t2fn4){ref-type="table-fn"}), (2*RS*)-**4** (nd[d](#t2fn4){ref-type="table-fn"})
  Chirazyme L-5 CA                         1.5                                        (2*RS*)-**5** (17), **1** (nd[d](#t2fn4){ref-type="table-fn"}), (2*RS*)-**4** (83)
                                           3.0                                        (2*RS*)-**5** (29), **1** (nd[d](#t2fn4){ref-type="table-fn"}), (2*RS*)-**4** (71)
  Chirazyme L-2 CB                         1.0                                        (2*RS*)-**5** (99), **1** (nd[d](#t2fn4){ref-type="table-fn"}), (2*RS*)-**4** (nd[d](#t2fn4){ref-type="table-fn"})

Enzyme concentration was 1.0 mg/mL. Initial concentration of (2*RS*)-**4** was 1.0 mM in 20 mM sodium citrate buffer (pH 5.0) containing 10% (v/v) DMSO.

Incubation time at 40 °C.

Yields based on HPLC analysis.

nd = not detected.

Both CALB and Chirazyme L-2 CB yielded (2*RS*)-**5** efficiently and quantitatively, with both the enzymes showing extremely high chemo-selectivity toward the methyl ester group of (2*RS*)-**4** without affecting the 1-β-*O*-acyl linkage. Chirazyme L-2 CB, whose specific activity is approximately one-half that of CALB, might be more a convenient enzyme than CALB: a CALB-derived impurity coelutes with the product (2*RS*)-**5** in the Amberlite XAD-4 column chromatography purification step, although this impurity can be removed prior to use of CALB as the enzymatic catalyst by adsorption onto XAD-4 resin (cf. [Experimental Section](#sec4){ref-type="other"}).

The purity of (2*RS*)-**5** as AG was assayed by ^1^H NMR and HPLC analyses. The anomeric β-configurations of the diastereomers (2*RS*)-**5** were confirmed by ^1^H NMR: the *J* values of both anomeric protons of the (2*S*)- and (2*R*)-**5** diastereomers were 8.2 Hz,^[@ref56]^ representative values for their β-configurations. HPLC analyses using an L-column2 ODS revealed that two peaks, corresponding to diastereomeric (2*RS*)-**5** (peaks a and b in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), were quantitatively hydrolyzed to the parent ALP **1** following treatment with β-glucuronidase at 37 °C for 20 min (peak c in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). The purity of (2*RS*)-**5** as AG was calculated to be over 99% (data not shown).

![Reversed-phase HPLC chromatograms of the synthesized (2*RS*)-**5** (peaks a and b in A), ALP **1** (peak c in B) liberated from (2*RS*)-**5** after treatment with β-glucuronidase (20 IU) for 20 min at pH 5.0 and 37 °C, and the synthesized (2*R*)-**5** (peak d in C) whose retention time was consistent with that of peak b in A.](ao-2018-00443d_0002){#fig2}

Synthesis of (2*R*)-**1** and Its AGs (2*R*)-**5** {#sec2.2}
--------------------------------------------------

We synthesized (2*R*)-**5** from (2*R*)-**1** and **2** to determine the absolute configuration at the chiral center α to the 1-β-*O*-acyl linkage of (2*RS*)-**5**. Compound (2*R*)-**1** was prepared in two steps starting from (*RS*)-2-(4-nitrophenyl)propanoic acid (2*RS*)-**6**, as shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Chiral resolution of (2*RS*)-**6** was achieved using a diastereomeric salt method.^[@ref57]^ The racemate (2*RS*)-**6** in ethyl acetate solution was treated with (*S*)-(−)-1-phenylethylamine to precipitate the (2*R*)-**6**-derived diastereomeric salt; after four recrystallizations, (2*R*)-**6** with 95.3% ee was obtained. The *R* configuration was confirmed by optical rotation measurements. Catalytic hydrogenation of (2*R*)-**6** to the corresponding amine (2*R*)-**7** followed by *N*-alkenylation^[@ref58]^ using excess amounts of 3-chloro-2-methyl-1-propene and potassium fluoride on Celite afforded (2*R*)-**1** with 95.4% ee. The chiral (2*R*)-**5** was synthesized from (2*R*)-**1** and **2** according to the methods shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C shows a typical reversed-phase HPLC chromatogram of (2*R*)-**5** (peak d); the retention time of this peak was consistent with that of peak b in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A.

![Synthesis of (2*R*)-ALP (2*R*)-**1**\
Reagents: (a) (*S*)-(−)-1-phenylethylamine, EtOAc, four recrystallizations (55%, 95.3% ee); (b) H~2~--Pd/C, MeOH, 4 h (92%); and (c) 3-chloro-2-methyl-1-propene, KF on Celite, CH~3~CN, 70 °C, 12 h (44%).](ao-2018-00443d_0006){#sch2}

Chiral Resolution of ALP **1** {#sec2.3}
------------------------------

Methods for the chiral resolution of several NSAIDs have been reviewed.^[@ref59]^ To our knowledge, though, there is no published stereospecific assays for **1** other than one paper in a Japanese journal^[@ref60]^ that reported the pharmacological activities of the [d]{.smallcaps}- and [l]{.smallcaps}-isomers of **1**. However, that paper did not describe the synthesis and structural characteristics of these isomers. We, therefore, attempted the chiral resolution of **1** and compared the retention times of the enantiomers with that of the synthesized (2*R*)-**1** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The enantiomers of **1** were well-separated from each other using a semipreparative CHIRALCEL OZ-H chiral HPLC column, and the comparison of the retention times was conducted using a CHIRALPAK IG analytical column. As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, the retention time of (2*R*)-**1** (peak c in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B) was consistent with that of the peak a in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A.

![Chiral HPLC chromatograms of **1** (peaks a and b in A) and (2*R*)-**1** (peak c in B). The retention times of the major peak c corresponding to (2*R*)-**1** and the minor peak d were consistent with those of peaks a and b in A, respectively.](ao-2018-00443d_0003){#fig3}

Kinetic Studies on the Degradation Reaction of (2*RS*)-**5** {#sec2.4}
------------------------------------------------------------

As was reported previously,^[@ref25]^ degradation rate constant (*k*) values of AGs in sodium phosphate buffer (100 mM, pH 7.4) at 37 °C have been demonstrated to consist of rate constants of intramolecular acyl migration and hydrolysis of their 1-β-*O*-acyl linkages. Because both the reactions are electrophilic ones, the more the *k* value increases, the higher the electrophilic reactivity of the corresponding AG becomes. Therefore, to estimate the electrophilic reactivity of (2*RS*)-**5**, their *k* values were determined by incubating (2*RS*)-**5** in sodium phosphate buffer (100 mM, pH 7.4) at 37 °C and analyzing changes with time by HPLC. As shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, the decreases in the concentrations of both (2*R*)-**5** and (2*S*)-**5** obeyed pseudo-first-order reaction kinetics in the time range spanning 3 or 4 half-lives. The major products were the corresponding intramolecular acyl-migrated isomers; the released ALP **1** was only 9% after 7 h (data not shown). The *k* value of (2*R*)-**5** was 0.405 ± 0.002 h^--1^ (the half-life was 1.71 h), which is approximately twice that of (2*S*)-**5** (the *k* value and the half-life were 0.226 ± 0.002 h^--1^ and 3.07 h, respectively). This result is in accordance with earlier reports that the (*R*)/(*S*) ratios of the *k* values for several 2-arylpropanoic acid-derived AGs are around 2.^[@ref61]^ These *k* values for (2*R*)- and (2*S*)-**5** are smaller than those of AGs derived from (2*R*)- and (2*S*)-phenylpropanoic acids, whose values were previously determined to be 0.604 ± 0.003 and 0.324 ± 0.008 h^--1^, respectively, under the same conditions and methods.^[@ref62]^ The lower reactivity of (2*R*)- and (2*S*)-**5** might be due partly to the electronic effect^[@ref23],[@ref63]^ of the electron-donating (2-methylallyl)amino substituent on (2*R*)- and (2*S*)-**5**; the Hammett substituent constant σ~p~ of this substituent is not found in the literature but estimated to be a negative value, judging from the σ~p~ values^[@ref64]^ of EtNH-- and CH~3~(CH~2~)~3~NH-- substituents being −0.61 and −0.51, respectively. Although there is no report for the Hammett reaction constant ρ value for AGs derived from *m*- and *p*-substituted (2*RS*)-phenylpropanoic acid derivatives and hence the theoretical *k* values of (2*R*)- and (2*S*)-**5** cannot be calculated, the theoretical *k* values can be predicted to be lower than those of AGs derived from (2*R*)- and (2*S*)-phenylpropanoic acids based on the estimated ρ value being positive.^[@ref62]^ Therefore, we next tried to calculate the *k* value of (2*R*)-**5**, based on the previously reported^[@ref25]^ linear relationship between log *k* of AGs and δ~COO*H*~ values of the parent carboxylic acids, a good positive correlation with a slope of 0.79. From the δ~COO*H*~ values (12.04 and 12.33 ppm for ALP **1** and 2-phenylpropanoic acid, respectively) and a log *k* value of −0.219 for AG derived from (2*R*)-phenylpropanoic acid,^[@ref62]^ the *k* value for (2*R*)-**5** was calculated to be 0.356, the value being close to the measured value.

![Time courses of the degradation reaction of (2*R*)-**5** (○) and (2*S*)-**5** (●) under physiological conditions (pH 7.40 and 37 °C). The *k* values of (2*R*)-**5** and (2*S*)-**5** were 0.405 ± 0.002 and 0.226 ± 0.002 h^--1^, respectively.](ao-2018-00443d_0004){#fig4}

Conclusions {#sec3}
===========

ALP-derived acyl glucuronides (2*RS*)-**5** were successfully prepared using our chemo-enzymatic method, and their chemical structures were fully characterized; the complete β-configuration of (2*RS*)-**5** was confirmed by ^1^H NMR as well as by exhaustive hydrolysis by β-glucuronidase. The intrinsic degradation rate constant of (2*R*)-**5** was approximately twice that of (2*S*)-**5** under physiological conditions (pH 7.40, 37 °C). The absolute stereochemistry of both ALP **1** and (2*RS*)-**5** was determined by comparison with chemically synthesized (2*R*)-**1** and (2*R*)-**5**, respectively. We have prepared the enantiomers of ALP **1** and developed the HPLC analytical conditions for these compounds. Further studies are in progress on the UGT isozyme(s) responsible for glucuronidation of **1**, the chiral inversion^[@ref65],[@ref66]^ from (2*R*)-**1** to (2*S*)-**1**, and the membrane transporters for both **1** and (2*RS*)-**5** in Caco-2 cells.

Experimental Section {#sec4}
====================

Materials and General Experimental Methods {#sec4.1}
------------------------------------------

Methyl 2,3,4-tri-*O*-acetyl-1-bromo-1-deoxy-α-[d]{.smallcaps}-glucopyranuronate **2** (Sigma), (*S*)-(−)-1-phenylethylamine (99+%; Acros), 3-chloro-2-methyl-1-propene (TCI), potassium fluoride on Celite (Aldrich), β-glucuronidase (type B-3, from bovine liver) (Sigma), PLE (esterase from porcine liver) (Sigma-Aldrich), LAS (lipase AS Amano from *Aspergillus niger*) (Wako), CSR (carboxylesterase from *S. rochei*, crude) (Wako), CALB (lipase type B from *C. antarctica*) (Wako), Chirazyme L-2 CB (lipase type B from *C. antarctica*) (Wako), and Chirazyme L-5 CA (lipase type A from *C. antarctica*) (Wako) were commercially available and used without purification. Alminoprofen (2*RS*)-**1**, the active ingredient of the commercially available drug Lumifen (manufacturer; Sato Pharmaceutical Co., Ltd), was isolated as described below. (*RS*)-2-(4-Nitrophenyl)propanoic acid (2*RS*)-**6** (Aldrich) was purified before use. Amberlite XAD-4 (ORGANO) was used after grinding and washing with acetone (80--200 mesh). All other chemicals used were analytical grade commercial products. Column chromatography was performed using silica gel 60 (40--63 μm). Thin-layer chromatography (TLC) was performed on precoated aluminum silica gel plates 60 (*F*~254~, 0.20 mm) or precoated glass silica gel plates 60 (F~254~, 0.5 mm) (Merck). Spots on the TLC plates were visualized under a UV lamp and/or by carbonization by spraying MeOH/H~2~O/H~2~SO~4~ = 1:1:2 (v/v) and heating the TLC plate. ^1^H (600 MHz) and ^13^C (151 MHz) NMR spectra were recorded on a JNM-ECA600 spectrometer, and chemical shits are presented as δ values with reference to the residual solvent signals of DMSO-*d*~6~ (2.50 and 39.50 ppm for ^1^H and ^13^C NMR, respectively) and MeOH-*d*~4~ (3.31 and 49.00 ppm for ^1^H and ^13^C NMR, respectively). Optical rotations were measured with a JASCO P-2300 polarimeter.

HPLC Apparatus and Analysis {#sec4.2}
---------------------------

Reactions were analyzed using a Shimadzu LC-10A equipped with an appropriate HPLC column, a Shimadzu SPD-10A VP UV detector (monitoring at 254 nm), and a Shimadzu CTO-10AS VP column oven set at 30 °C. The HPLC columns used were CHIRALCEL OZ-H (DAICEL; 5 μm, 10 × 250 mm^2^) for chiral resolution, CHIRALPAK IG (DAICEL; 5 μm, 4.6 × 250 mm^2^) for determination of the enantiomeric purity of the chiral compounds, symmetry *C*~18~ (Waters; 5 μm, 4.6 × 150 mm^2^) for quantitative analysis of the chemical reaction products, and L-column2 ODS (CERI; 5 μm, 4.6 × 150 mm^2^) for kinetic studies of the degradation reaction of (2*RS*)-**5**.

Isolation of ALP **1** {#sec4.3}
----------------------

ALP **1** was isolated from 12 Lumifen tablets containing a total of 2.4 g of **1**. The tablets were crushed and extracted twice with ethyl acetate (each 80 mL) by stirring for 5 min. The combined organic extracts were washed with water (50 mL), dried over Na~2~SO~4~, filtered, and then concentrated under reduced pressure. The resultant crude product was purified by recrystallization to afford **1** (2.04 g) in 85% yield: mp 106--107 °C (white crystals from EtOH--H~2~O) (lit.,^[@ref45]^ 107 °C). Found: C, 71.20; H, 7.93; N, 6.34 C~13~H~17~NO~2~ requires C, 71.21; H, 7.81; N, 6.39; HRMS (ESI, positive): \[M + H\]^+^ calcd for C~13~H~18~NO~2~, *m*/*z* 220.1332; found, *m*/*z* 220.1339 (error 0.7 mmu); ^1^H NMR (600 MHz, DMSO-*d*~6~): δ 12.04 (br s, 1H, COO*H*, exchangeable with D~2~O), 6.95 (d, 2H, *J* = 8.6 Hz, Ar*H*), 6.48 (d, 2H, *J* = 8.6 Hz, Ar*H*), 5.83 (br s, 1H, N*H*, exchangeable with D~2~O), 4.88 (br s, 1H, C=C*H*~2~), 4.79 (br s, 1H, C=C*H*~2~), 3.55 (br s, 2H, NHC*H*~2~), 3.44 (q, 1H, *J* = 7.2 Hz, C*H*CH~3~), 1.70 (s, 3H, CH~2~=CC*H*~3~), 1.27 (d, 3H, *J* = 7.2 Hz, CHC*H*~3~); ^13^C NMR (151 MHz, DMSO-*d*~6~): δ 175.9 (*C*OOH), 147.6, 143.0, 127.9, 127.6, 111.9, 110.1, 48.7, 43.7, 20.1, 18.6.

Optical Resolution of **1** {#sec4.4}
---------------------------

Optical resolution was performed using a CHIRALCEL OZ-H chiral preparative column equilibrated with *n*-hexane/EtOH/AcOH = 90/10/0.1 (v/v) at a flow rate of 2.5 mL/min. A 200 μL aliquot of 9.0 mg/mL **1** in the mobile phase was injected onto the column for each separation. The retention times of (2*R*)-**1** and (2*S*)-**1** were 19.0 and 15.5 min, respectively. Both enantiomers were almost completely resolved, and their optical purities (% ee) were each \>99%. The absolute configuration of the chiral center was unambiguously determined by confirming the retention time of the (2*R*)-**1** enantiomer and that of authentic (2*R*)-**1** synthesized from (2*R*)-2-(4-nitrophenyl)propanoic acid (2*R*)-**6** (see below). Chiral HPLC was conducted using a CHIRALPAK IG analytical column equilibrated with 55% (v/v) MeOH containing 56 mM formic acid (pH 2.1) at a flow rate of 0.8 mL/min and monitored at 254 nm. The retention times of (2*R*)-**1** and (2*S*)-**1** were 15.9 and 18.8 min, respectively. The specific optical rotation \[α\]~D~^26^ values of (2*R*)-**1** and (2*S*)-**1** were −57° (*c* = 0.42, EtOH) and +60° (*c* = 0.30, EtOH), respectively.

Synthesis of (2*R*)-**1** from (2*R*)-**6** Obtained by Optical Resolution of (2*RS*)-**6** {#sec4.5}
-------------------------------------------------------------------------------------------

Commercially available (2*RS*)-**6** was purified by column chromatography (silica gel; CHCl~3~/MeOH/AcOH = 100/1/1) followed by charcoal treatment to remove impurities and colored components. Optical resolution of purified (2*RS*)-**6** was performed by a diastereomeric salt method^[@ref57]^ using (*S*)-(−)-1-phenylethylamine as follows: To a stirred solution of the purified (2*RS*)-**6** (1.02 g, 5.23 mmol) in EtOAc (50 mL) was added (*S*)-(−)-1-phenylethylamine (0.34 mL, 2.6 mmol) to afford a white precipitate. The mixture was heated to reflux, and then the clear solution was allowed to stand at room temperature. The precipitated white needles were collected and recrystallized from EtOAc (50 mL) to afford (2*R*)-**6**-derived salt (552 mg). The optical purity (% ee) was 87.4% as determined using a CHIRALPAK IG chiral column equilibrated with *n*-hexane/EtOH/TFA = 800:200:1 (v/v) at a flow rate of 0.6 mL/min. The retention times of (2*R*)-**6** and (2*S*)-**6** were 10.5 and 12.2 min, respectively. A fourth recrystallization using the same conditions as described above increased the percent enantiomeric excess (% ee) of the (2*R*)-**6**-derived salt (400 mg) to 95.2%. The salt was next treated with EtOAc (30 mL) and 0.33 M HCl (10 mL) saturated with NaCl, and then the organic layer was dried over Na~2~SO~4~. After evaporation of the organic solvent under reduced pressure, (2*R*)-**6** (281 mg, 55%) was obtained as a white solid with a % ee of 95.3%. The *R* configuration was confirmed by its \[α\]~D~^25^ value of −53.1° (*c* = 0.565, CHCl~3~), which is comparable to the reported value (lit.,^[@ref67]^ \[α\]~D~^25^ −55.3°). Catalytic hydrogenation of (2*R*)-**6** (220 mg, 1.13 mmol) was performed in MeOH (3.0 mL) with 10% Pd--C (20 mg) at room temperature for 4 h to afford the corresponding (*R*)-2-(4-aminophenyl)propionic acid (2*R*)-**7** as a pale pink solid (171 mg, 92%). HRMS (ESI, positive): \[M + H\]^+^ calcd for C~9~H~12~NO~2~, *m*/*z* 166.0869; found, *m*/*z* 166.0863 (error 0.6 mmu). The final step of *N*-(2-methyl)allylation of (2*R*)-**7** (96 mg, 0.58 mmol) was performed at 70 °C with 3-chloro-2-methyl-1-propene (83 μL, 0.85 mmol) and KF--Celite^[@ref51]^ (150 mg) in CH~3~CN (2.5 mL) for 12 h. After removal of the insoluble materials, the solvent from filtrate was evaporated under reduced pressure to afford crude solid, which was purified by preparative TLC to afford (2*R*)-**1** (57 mg, 44%). The retention time and optical purity (% ee) of (2*R*)-**1** obtained were 15.9 min and 95.4%, respectively, using a CHIRALPAK IG chiral column equilibrated with 55% (v/v) MeOH containing 56 mM formic acid (pH 2.1) at a flow rate of 0.8 mL/min and monitored at 254 nm.

Synthesis of Methyl 1-β-*O*-2-{4-\[(2-Methylprop-2-en-1-yl)amino\]phenyl}propanoyl-2,3,4-tri-*O*-acetyl-[d]{.smallcaps}-glucopyranuro-nate (2*RS*)-**3** (Mixture of Two Diastereomers) {#sec4.6}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a stirred solution of (2*RS*)-**1** (493 mg, 2.25 mmol) in 8.0 mL of EtOH, 2.25 mL of 0.50 mol/L aqueous Cs~2~CO~3~ was added. After brief sonication to dissolve the cesium salt, the mixture was concentrated under reduced pressure. To remove water, EtOH (3.0 mL) was added to the residue and the solvent was removed under reduced pressure. The residue was dissolved with 20 mL of DMSO, and then methyl 2,3,4-tri-*O*-acetyl-1-bromo-1-deoxy-α-[d]{.smallcaps}-glucopyranuronate **2** (1.14 g, 2.72 mmol) was added at room temperature with vigorous stirring. The reaction was monitored by HPLC using a symmetry *C*~18~ column eluted with 50% (v/v) CH~3~CN containing 25 mM ammonium acetate (pH 4.5) and 10 mM tetra-*n*-butylammonium bromide at a flow rate of 0.5 mL/min and monitored at 254 nm. The retention times of (2*RS*)-**1** and (2*RS*)-**3** were 8.15 and 36.5 min, respectively. After 3 h, the reaction mixture was diluted with 200 mL of ethyl acetate and then washed three times with water (each 70 mL), four times with 0.1 mol/L NaOH (each 40 mL), and then once with saturated saline (70 mL). After drying over Na~2~SO~4~, the organic solvent was evaporated under reduced pressure. Column chromatography (silica; EtOAc/benzene = 2/5) of the residue afforded (2*RS*)-**3** (663 mg) as a colorless syrup in 53% yield. HRMS (ESI, positive): \[M + Na\]^+^ calcd for C~26~H~33~NO~11~Na, *m*/*z* 558.1946; found, *m*/*z* 558.1954 (error 0.8 mmu); ^1^H NMR (600 MHz, MeOH-*d*~4~): δ 7.00 (d, 2H, *J* = 8.6 Hz), 6.97 (d, 2.1H, *J* = 8.6 Hz), 6.54 (d, 2H, *J* = 8.6 Hz), 6.53 (d, 2.1H, *J* = 8.6 Hz), 5.85 (d, 1H, *J* = 8.2 Hz), 5.78 (d, 1.06H, *J* = 8.2 Hz), 5.40 (t, 1H, *J* = 9.3 Hz), 5.35 (d, 1.06H, *J* = 9.3 Hz), 5.13 (t, 1H, J = 9.6 Hz), 5.10 (t, 1.06H, *J* = 9.6 Hz), 5.08 (dd, 1H, *J* = 8.2 and 9.6 Hz), 4.98 (dd, 1.06H, *J* = 8.2 and 9.6 Hz), 4.93--4.92 (m, 2.1H), 4.83--4.82 (m, 2.1H), 4.41 (d, 1.06H, *J* = 9.6 Hz), 4.39 (d, 1H, *J* = 9.6 Hz), 3.72 (s, 3.2H), 3.69 (s, 3H), 3.64--3.59 (m, 6.2H), 2.00 (s, 6.2H), 1.98 (s, 3H), 1.95 (s, 3.2H), 1.87 (s, 3H), 1.75 (s, 3.2H), 1.74 (s, 3H), 1.57 (s, 3.2H), 1.43 (d, 3H, *J* = 7.2 Hz), 1.38 (d, 3.2H, *J* = 7.2 Hz); ^13^C NMR (151 MHz, MeOH-*d*~4~): δ 174.6, 174.2, 171.4, 171.3, 171.2, 170.9, 170.7, 168.9, 149.7, 144.5, 129.1, 129.0, 128.7, 128.1, 114.0, 113.97, 111.1, 92.7, 92.6, 73.7, 73.65, 73.3, 73.1, 71.5, 71.2, 70.7, 53.4, 50.6, 50.58, 46.0, 45.4, 20.6, 20.54, 20.5, 20.46, 20.4, 18.4, 18.3.

Enzyme-Catalyzed Chemo-Selective Removal of the *O*-Acetyl Groups of (2*RS*)-**3** to (2*RS*)-**4** {#sec4.7}
---------------------------------------------------------------------------------------------------

Of the trials for the enzymatic *O*-deacetylation of (2*RS*)-**3** using LAS and CSR, concurrent use of LAS and CSR (1:10, w/w) proved to be the most effective and exhibited the highest chemo-selective activity. To a stirred solution of (2*RS*)-**3** (108 mg, 0.202 mmol) in 15 mL of DMSO at 40 °C was added a solution of LAS (50 mg; 0.5 mg/mL incubation mixture) and CSR (550 mg; 5.5 mg/mL incubation mixture) in 85 mL of 25 mM sodium citrate buffer (pH 5.0) thermally pre-equilibrated at 40 °C. The mixture was gently stirred for 15 min at 40 °C, and then the temperature was raised to 50 °C. After a total of 7 h of incubation, the conversion yield to methyl 1-β-*O*-2-{4-\[(2-methylprop-2-en-1-yl)amino\]phenyl}propanoyl-[d]{.smallcaps}-glucopyranuronate (2*RS*)-**4** was calculated to be 94% by HPLC using a symmetry *C*~18~ column eluted with 35% (v/v) CH~3~CN containing 25 mM ammonium acetate (pH 4.5) and 10 mM tetra-*n*-butylammonium bromide at a flow rate of 0.5 mL/min and monitored at 254 nm. The retention times of **1** and (2*RS*)-**4** were 23.7 and 16.3 min, respectively. The product was extracted with EtOAc (50 mL × 3), and the organic solvent was evaporated under reduced pressure to afford crude (2*RS*)-**4**. A part of the sample was purified by TLC for HRMS analysis. HRMS (ESI, positive): \[M + Na\]^+^ calcd for C~20~H~27~NO~8~Na, *m*/*z* 432.1629; found, *m*/*z* 432.1630 (error 0.1 mmu); ^1^H NMR (600 MHz, MeOH-*d*~4~): δ 7.04 (d, 2H, *J* = 8.6 Hz), 7.02 (d, 2H, *J* = 8.6 Hz), 6.56 (d, 2H, *J* = 8.6 Hz), 6.55 (d, 2H, *J* = 8.6 Hz), 5.47 (d, 1H, *J* = 8.2 Hz), 5.45 (d, 1H, *J* = 8.2 Hz), 4.93 (br s, 2H), 4.83 (br s, 2H), 3.94 (d, 1H, *J* = 9.6 Hz), 3.91 (d, 1H, *J* = 9.6 Hz), 3.77 (s, 3H), 3.74 (s, 3H), 3.67 (q, 1H, *J* = 7.2 Hz), 3.66 (q, 1H, *J* = 7.2 Hz), 3.64 (br s, 4H), 3.54 (t, 1H, *J* = 9.6 Hz), 3.51 (t, 1H, *J* = 9.6 Hz), 3.43 (t, 1H, *J* = 9.2 Hz), 3.41 (t, 1H, *J* = 9.2 Hz), 3.37 (dd, 1H, *J* = 8.2 and 9.2 Hz), 3.35 (dd, 1H, *J* = 8.2 and 9.2 Hz), 1.75 (s, 6H), 1.43 (d, 3H, *J* = 7.2 Hz), 1.42 (d, 3H, *J* = 7.2 Hz); ^13^C NMR (151 MHz, MeOH-*d*~4~): δ 175.5, 175.4, 170.83, 170.81, 149.4, 144.5, 129.1, 129.0, 114.0, 113.9, 111.0, 95.7, 77.3, 73.6, 73.5, 72.91, 72.89, 52.9, 50.69, 50.66, 45.68, 45.65, 20.4, 19.3, 19.2.

Enzyme-Catalyzed Chemo-Selective Hydrolysis of the Methyl Ester of (2*RS*)-**4** to (2*RS*)-**5** {#sec4.8}
-------------------------------------------------------------------------------------------------

Of the enzymes tested, CALB and Chirazyme L-2 CB showed high chemo-selective activities, yielding almost quantitatively the product (2*RS*)-**5** (see [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The hydrolytic reaction was monitored by HPLC using a symmetry *C*~18~ column eluted with 35% (v/v) CH~3~CN containing 25 mM ammonium acetate (pH 4.5) and 10 mM tetra-*n*-butylammonium bromide at a flow rate of 0.5 mL/min. (1) Method with CALB. CALB (2.0 mg/mL 25 mM sodium citrate buffer, pH 5.0) was treated with XAD-4 resin wetted (80--200 mesh, 40 mg) in an ice water bath for 5 min with gentle shaking to remove impurities. Hydrolysis of (2*RS*)-**4** with the abovementioned CALB (a final concentration of 1.0 mg/mL) was performed at 40 °C with an initial concentration of 1.0 mM (2*RS*)-**4** in 20 mM sodium citrate buffer (pH 5.0) containing 10% (v/v) DMSO. (2) Method with Chirazyme L-2 CB. Hydrolysis of (2*RS*)-**4** with Chirazyme L-2 CB (a final concentration of 1.0 mg/mL) was performed at 40 °C with an initial concentration of 1.0 mM (2*RS*)-**4** in 20 mM sodium citrate buffer (pH 5.0) containing 10% (v/v) DMSO. The concentration of the substrate (2*RS*)-**4** was able to rise to 4 mM. (3) Isolation of (2*RS*)-**5**. After 1.5 h of the incubation starting from 0.22 mmol of (2*RS*)-**4** and 55 mg of Chirazyme L-2 CB, the mixture (55 mL) was loaded onto an XAD-4 column (10 g, 1.6 cm i.d.), which had been washed thoroughly with acetone and then equilibrated with aqueous water. The column was washed with 50 mL of water, 200 mL of 4 mM HCl, and then 50 mL of water. The product (2*RS*)-**5** was eluted with 200 mL of 20% (v/v) aqueous CH~3~CN. Fractions containing (2*RS*)-**5** were pooled, the solvent was evaporated under reduced pressure, and the residue was dried over P~2~O~5~ in a vacuum desiccator to afford a pale yellow solid (83 mg, 95%). HRMS (ESI, negative): \[M -- H\]^−^ calcd for C~19~H~24~NO~8~, *m*/*z* 394.1507; found, *m*/*z* 394.1518 (error 1.1 mmu); ^1^H NMR (600 MHz, MeOH-*d*~4~): δ 7.06 (d, 2H, *J* = 8.6 Hz), 7.04 (d, 2H, *J* = 8.6 Hz), 6.57 (d, 4H, *J* = 8.6 Hz), 5.48 (d, 1H, *J* = 7.9 Hz), 5.47 (d, 1H, *J* = 7.9 Hz), 4.93 (br s, 2H), 4.84 (br s, 2H), 3.89 (d, 1H, *J* = 9.6 Hz), 3.86 (d, 1H, *J* = 9.6 Hz), 3.69 (q, 1H, *J* = 7.2 Hz), 3.68 (q, 1H, *J* = 7.2 Hz), 3.64 (br s, 4H), 3.53 (t, 1H, *J* = 9.6 Hz), 3.51 (t, 1H, *J* = 9.6 Hz), 3.44 (t, 1H, *J* = 9.1 Hz), 3.42 (t, 1H, *J* = 9.1 Hz), 3.39--3.34 (m, 2H), 1.75 (s, 6H), 1.44 (d, 3H, *J* = 7.2 Hz), 1.43 (d, 3H, *J* = 7.2 Hz); ^13^C NMR (151 MHz, MeOH-*d*~4~): δ 175.5, 175.4, 172.1, 149.2, 149.1, 144.34, 143.31, 129.5, 129.4, 129.1, 114.2, 114.1, 111.2, 111.1, 95.7, 77.5, 77.22, 77.16, 73.6, 72.92, 72.89, 50.85, 50.79, 45.7, 20.4, 19.3, 19.2.

Synthesis of (2*R*)-**5** through Methyl 1-β-*O*-2-{4-\[(2-Methylprop-2-en-1-yl)amino\]phenyl}propanoyl-2,3,4-tri-*O*-acetyl-[d]{.smallcaps}-glucopyranuronate (2*R*)-**3** {#sec4.9}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In accordance to the abovementioned procedure for the synthesis of (2*RS*)-**3**, the cesium salt prepared from (2*R*)-**1** (25 mg, 0.11 mmol) was reacted with methyl 2,3,4-tri-*O*-acetyl-1-bromo-1-deoxy-α-[d]{.smallcaps}-glucopyranuronate (**2**) (57 mg, 0.14 mmol) at room temperature for 2 h to afford (2*R*)-**3** (25 mg) in 40% yield. HRMS (ESI, positive): \[M + Na\]^+^ calcd for C~26~H~33~NO~11~Na, *m*/*z* 558.1946; found, *m*/*z* 558.1959 (error 1.3 mmu); ^1^H NMR (600 MHz, MeOH-*d*~4~): δ 6.96 (d, 2H, *J* = 8.6 Hz), 6.52 (d, 2H, *J* = 8.6 Hz), 5.78 (d, 1H, *J* = 8.2 Hz), 5.34 (t, 1H, *J* = 9.6 Hz), 5.09 (t, 1H, *J* = 9.6 Hz), 4.97 (dd, 1H, *J* = 8.2 and 9.6 Hz), 4.91 (br s, 1H), 4.82 (br s, 1H), 4.41 (d, 1H, *J* = 9.6 Hz), 3.71 (s, 3H), 3.62 (s, 2H), 3.59 (q, 1H, *J* = 7.2 Hz), 2.00 (s, 3H), 1.95 (s, 3H), 1.74 (s, 3H), 1.57 (s, 3H), 1.38 (d, 3H, J = 7.2 Hz); ^13^C NMR (151 MHz, MeOH-*d*~4~): δ 174.5, 171.2, 171.1, 170.6, 168.8, 149.6, 144.5, 129.0, 128.7, 113.9, 111.0, 92.5, 73.6, 73.1, 71.1, 70.7, 53.4, 50.5, 45.3, 20.44, 20.38, 20.36, 20.32, 18.3. According to the above procedures described for the preparation of (2*RS*)-**5** from (2*RS*)-**3**, enzyme-catalyzed chemo-selective hydrolysis of the sugar-protecting groups of (2*R*)-**3** was performed using LAS and CSR followed by using Chirazyme L-2 CB to afford (2*R*)-**5**. HRMS (ESI, negative): \[M -- H\]^−^ calcd for C~19~H~24~NO~8~, *m*/*z* 394.1507; found, *m*/*z* 394.1513 (error 0.6 mmu).

Measurement of the Intrinsic Degradation Rate Constants (*k* Values) of (2*RS*)-**5** {#sec4.10}
-------------------------------------------------------------------------------------

The *k* values of (2*RS*)-**5** (an initial concentration of 0.10 mM) were measured under physiological conditions (100 mM sodium phosphate buffer at pH 7.40 and 37 °C). The degradation reaction was monitored by HPLC using an L-column2 ODS eluted with 30% (v/v) CH~3~CN containing 25 mM ammonium acetate (pH 4.5) and 10 mM tetra-*n*-butylammonium bromide at a flow rate of 0.5 mL/min and monitored at 254 nm. Aliquots of the reaction mixture sampled at appropriate intervals were diluted with the HPLC mobile phase and kept in an ice bath until HPLC analysis. The HPLC mobile phase was slightly acidic to prevent further degradation of both the starting compounds and the resultant acyl-migrated compounds before and during HPLC analysis. Using these optimized HPLC conditions, the retention times of (2*R*)-**5** and (2*S*)-**5** were 29.1 and 30.2 min, respectively.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b00443](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b00443).^1^H and ^13^C NMR spectra and mass spectra for ALP **1** and all new compounds (2*RS*)-**3**, (2*R*)-**3**, (2*RS*)-**4**, (2*RS*)-**5**, and (2*RS*)-**7** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00443/suppl_file/ao8b00443_si_001.pdf))
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ALP

:   alminoprofen

NSAID

:   nonsteroidal anti-inflammatory drug

UGT

:   UDP-glucuronosyltransferase

LAS

:   lipase AS Amano

CSR

:   carboxylesterase from *Streptomyces rochei*

PLE

:   pig liver esterase

CALB

:   lipase type-B from *Candida antarctica*

DMF

:   *N*,*N*-dimethylformamide

DMSO

:   dimethyl sulfoxide
